Guidance
← Earnings Calls
01
02
03
04 05 06
Tone
Capex
A1 A2 A3 A4
CTVA
FY2026 Q2
Improving
Corteva, Inc. earnings call
Buzzberg read
Full-year guidance raised with EBITDA and EPS increases.
Corteva beat expectations in Q2 and raised full-year 2026 guidance on strong execution in seed and crop protection. The company is on track to complete its separation on October 1st, with management outlining a clear path to meeting long-term targets. Key drivers are technology adoption, licensing growth, and cost/productivity improvements, offset by competitive pricing pockets in Brazil. Raised 2026 guidance: EBITDA to $4.1-4.3B, EPS to $3.60-3.80, margin to 22.5-23.5%.
Buzzberg read Full-year guidance raised with EBITDA and EPS increases. Corteva beat expectations in Q2 and raised full-year 2026 guidance on strong execution in seed and crop protection. The company is on track to complete its separation on October 1st, with management outlining a clear path to meeting long-term targets. Key drivers are technology adoption, licensing growth, and cost/productivity improvements, offset by competitive pricing pockets in Brazil. Raised 2026 guidance: EBITDA to $4.1-4.3B, EPS to $3.60-3.80, margin to 22.5-23.5%. Read full analysisCollapse analysis
Corteva beat expectations in Q2 and raised full-year 2026 guidance on strong execution in seed and crop protection. The company is on track to complete its separation on October 1st, with management outlining a clear path to meeting long-term targets. Key drivers are technology adoption, licensing growth, and cost/productivity improvements, offset by competitive pricing pockets in Brazil. Raised 2026 guidance: EBITDA to $4.1-4.3B, EPS to $3.60-3.80, margin to 22.5-23.5%.
- H1 2026: Sales up 4% to $11.3B, EBITDA up 10% to $3.7B, margin up 190bps to 32.8%.
- Separation (Vylor) on track for Oct 1, with net synergies impact largely offset to a ~$25M headwind for 2026.
- Crop protection new product portfolio on track to reach $2B revenue this year, offsetting price declines in generics.
Revenue$6.379B+30% QoQ
EPS$2.30+53% QoQ
Gross margin54.35%Reported
Operating margin30.02%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Separation
Separation on track for October 1 with minimal dis-synergies.
Crop Protection
Crop protection new products approaching $2 billion revenue.
Show 3 more callouts
Seed
Seed licensing business three years ahead of plan.
Pricing
Brazil crop protection pricing remains under pressure.
Demand
Brazilian farmer credit tightness noted as a watch item.
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $6.379B | +30% QoQ |
| EPS | $2.30 | +53% QoQ |
| Gross margin | 54.35% | Reported |
| Operating margin | 30.02% | Reported |
| Free cash flow | $-3.56B | -20% QoQ |
| Capex | $0.203B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $3.60–$3.80 | $3.70 | Raised |
| Operating margin | FY2026 | 22.5%–23.5%In line with consensus | 23% | Raised |
| Operating margin | FY2026 | $4.1B–$4.3B | $4.2B | Raised |
AI, capex & demand read
Management read
Confident
Management expressed confidence in raising full-year guidance, highlighted strong execution, and emphasized on-track separation progress, all conveying a positive outlook.
Investment and capacity
Management discussed productivity improvements, cost management, and asset optimization, but no specific forward-looking capex figures were provided.
External signals
Supply-chain alpha · 4returns since call
Corteva's licensing business is running three years ahead of plan, contributing to the 'net royalty positive' position for the first time.
Evidence
“licensing is literally three years ahead of our original plan, which is pretty astonishing considering that is a brand new business for us.”
Corteva anticipates a Q3 operating EBITDA loss of ~$100M, more typical of past years, with H2 EBITDA expected to be flat at ~$500M.
Evidence
“if you recall, our second half in 2025 was up 16% versus 2024. So we are comparing against a pretty strong half at about $500 million. ... Our second half is about 12% of our full year guide. And that's very much in line with the past four…”
Management states that the China-to-Brazil export market is stable, and the channel is not oversupplied, ready for the next season. This suggests the prior high-import inventory deluge is over.
Evidence
“when you look at Chinese exports into Brazil, they're essentially stable. They're not going down, but they're certainly not going up.”
Corteva is seeing competitive tension and price declines on off-patent molecules (e.g., pre-emergent herbicides in Brazil), but it has pre-emptively lowered its cost base on these products, allowing it to maintain margins and share.
Evidence
“We were really anticipating that we were going to see generic pressure. And we went really to work on our cost structure. And what we found is that we had to, of course, lower our prices because there's generics in the marketplace. But if…”
Methodology & coverage
Management-only analysis. All 0 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.